Biogen’s Apellis Acquisition Spurs SmallCap 600 Removal on May 14
BIIB•Biogen Inc’s pending acquisition of Apellis Pharmaceuticals will result in Apellis Pharmaceuticals’ removal from the S&P SmallCap 600 on May 14 ahead of the deal’s closing. The vacancy will be filled by Remitly Global, and Bright Horizons Family Solutions will replace Tri Pointe Homes, shifting sector allocations in the index.
1. Index Rebalance Details
Effective May 14, the S&P SmallCap 600 will delete Apellis Pharmaceuticals and Tri Pointe Homes, adding Remitly Global and Bright Horizons Family Solutions to the index.
2. Biogen’s Acquisition of Apellis
Biogen Inc is set to acquire Apellis Pharmaceuticals pending closing conditions, prompting Apellis’s exit from the SmallCap 600 prior to the deal’s completion.
3. Potential Market Impact
The reshuffle shifts health care and consumer discretionary weightings, which could influence small-cap sector performance and Biogen’s stock behavior as the acquisition advances.
